Dana E. Rathkopf, MD
Genitourinary Medical Oncologist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
About Me
- Attending Physician
- Chair, Research Council
I am a board-certified medical oncologist who treats people with prostate cancer and other genitourinary cancers. My primary focus is on the medical treatment of men with advanced or high-risk prostate cancer. I have been doing this work for more than a decade.
Read more
I also develop and design clinical trials testing new treatments for men with prostate cancer. I have had a leadership role in the development of clinical trials using androgen receptor (AR)-targeted therapies (such as abiraterone, enzalutamide, and apalutamide) for patients with advanced prostate cancer. The survival benefits shown in these trials changed the standard of care for patients with advanced disease. I am now focused on improving outcomes for patients in need of additional treatments by using new AR-directed therapies and combinations of targeted agents.
On a national level, I am the site principal investigator at Memorial Sloan Kettering Cancer Center for the Department of Defense Prostate Cancer Clinical Trials Consortium (PCCTC), an initiative designed to increase patient access to clinical trials across the country. I also serve as Chair of the Research Council at MSK, which is charged with ensuring the scientific merit and progress of our patient-facing research portfolio.
Although I do a lot of work with clinical trials in an effort to bring new and effective treatment options into clinical practice, my first priority is always my patients. Many of them ask me why I became interested in a disease that only affects men. In addition to my interests in the unique biology of the prostate cancer disease pathway and the opportunity to work with extraordinary mentors and colleagues, I am also a daughter, wife, and mother of three sons. The choice to pursue a career in prostate cancer was an easy one for me.
A genitourinary (jeh-nih-toh-YOOR-ih-nayr-ee) medical oncologist is a cancer doctor who specializes in genitourinary (GU) cancers. This includes bladder, kidney, penis, prostate, and testicular cancers.
My Specialties
- Prostate Cancer
- Clinical Trials
Education
- MD, Tulane School of Medicine
Residencies
- Internal Medicine - New York University Hospital
Awards and Honors
- Castle Connolly: Exceptional Women in Medicine (2024)
- Castle Connolly: America’s Top Doctor (2024)
- Top Doctors New York Metro Area, Castle Connolly (2023)
- Exceptional Women in Medicine Award, Castle Connolly (2023)
- Castle Connolly: America's Top Doctors (2023)
- Castle Connolly: New York Magazine Top Doctors (2019-2022)
- Excellence in Internal Medicine, American College of Physicians
- ASCO/AACR (American Association for Cancer Research) Workshop: Methods in Clinical Cancer Research, ASCO Merit Award
- Prostate Cancer Foundation Young Investigator Award
- SU2C Catalyst Award
Fellowships
- Medical Oncology/Hematology - Memorial Sloan Kettering Cancer Center
- Medicine - Weill Cornell Medical College
Board Certifications
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Dr. Rathkopf sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Rathkopf
- A Phase 3 Study of Apalutamide With Androgen-Deprivation Therapy in People With Advanced Prostate Cancer
- A Phase I Study of CC-94676 in Men with Metastatic Castration-Resistant Prostate Cancer
- Clinical Trials Co-Investigated by Dr. Rathkopf
- Two Studies for Patients with Unfavorable Intermediate-Risk Prostate Cancer Assessing Less Intense Treatment for Those With a Low Gene Risk Score and a More Intense Treatment for Those with a Higher Gene Risk Score
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Abiraterone in metastatic prostate cancer without previous chemotherapy
Enzalutamide in metastatic prostate cancer before chemotherapy
Visit PubMed for a full listing of Dr. Rathkopf’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Dana E. Rathkopf discloses the following relationships and financial interests:
-
AstraZeneca
Professional Services and Activities (Uncompensated) -
Bayer
Professional Services and Activities (Uncompensated) -
Bristol-Myers Squibb
Professional Services and Activities (Uncompensated) -
Genentech
Professional Services and Activities (Uncompensated)
-
Janssen Research & Development, LLC
Professional Services and Activities (Uncompensated) -
Myovant Sciences
Professional Services and Activities (Uncompensated) -
Promontory Therapeutics Inc.
Professional Services and Activities (Uncompensated)
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].